Vol. 3 No. 2 (2023)
Reimbursement Reviews

Dalbavancin (Xydalba)

Published February 23, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses Dalbavancin (Xydalba) for injection, 500 mg (as dalbavancin hydrochloride) per vial, lyophilized powder for solution, IV infusion.
  • Indication: Treatment of adults with acute bacterial skin and skin structure infections caused by susceptible isolates of the following gram-positive micro-organisms: Staphylococcus aureus (including methicillin-susceptible and methicillin-resistant strains), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus dysgalactiae, Streptococcus anginosus group (including Streptococcus anginosus, Streptococcus intermedius, Streptococcus constellatus), and Enterococcus faecalis (vancomycin-susceptible strains).